Jump to main content
Jump to site search

Issue 10, 2014
Previous Article Next Article

Antisense oligonucleotides: modifications and clinical trials

Author affiliations

Abstract

There has been an upsurge in the number of clinical trials involving chemically modified oligonucleotide-based drug candidates after the FDA approval of Vitravene, Macugen, and recently, Kynamro. Over the years, different types of backbone, nucleobase and/or sugar-modified oligonucleotides have been synthesized because natural DNA/RNA based oligonucleotides pose some limitations, such as poor binding affinity, low degree of nuclease resistance, affecting their direct use in antisense therapeutics. In this review article, we discuss in detail different modifications of nucleosides/oligonucleotides along with the related clinical trials, which demonstrated their potential as drug candidates for antisense and related nucleic acid based therapeutics.

Graphical abstract: Antisense oligonucleotides: modifications and clinical trials

Back to tab navigation

Publication details

The article was received on 23 Apr 2014, accepted on 29 Jul 2014 and first published on 01 Aug 2014


Article type: Review Article
DOI: 10.1039/C4MD00184B
Citation: Med. Chem. Commun., 2014,5, 1454-1471

  •   Request permissions

    Antisense oligonucleotides: modifications and clinical trials

    V. K. Sharma, R. K. Sharma and S. K. Singh, Med. Chem. Commun., 2014, 5, 1454
    DOI: 10.1039/C4MD00184B

Search articles by author

Spotlight

Advertisements